A new class of combination therapy within immuno-oncology.

Activated innate immune cells deliver an oncolytic virus.

Intravenous delivery to solid & non-solid tumors.

Safety and toxicity of each component previously tested and established in humans.

Target to effector ratio is 1:1,000,000; allows de-bulking of large tumors.

Multi-mechanistic, so broadly applicable to several indications.

Durable immune response and thus potentially curative.